Incyte logo

IncyteNASDAQ: INCY

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

04 November 1993

Next earnings report:

13 February 2025

Last dividends:

N/A

Next dividends:

N/A
$14.74 B
-23%vs. 3y high
94%vs. sector
546.64
0%vs. 3y high
100%vs. sector
-10%vs. 3y high
81%vs. sector
-38%vs. 3y high
51%vs. sector

Price

regular market | 13 min ago
$76.53-$0.07(-0.09%)

Dividend

No data over the past 3 years
$1.14 B$1.14 B
$1.14 B$106.46 M

Analysts recommendations

Institutional Ownership

INCY Latest News

Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff
seekingalpha.com31 October 2024 Sentiment: POSITIVE

Incyte announced impressive revenue growth of 24% in the third quarter, largely due to Jakafi and Opzelura. The approval of new products, such as Niktimvo, is expected to help diversify Incyte's income and lessen its dependence on Jakafi. The earnings per share (EPS) shortfall is mainly due to high research and development costs, which are important to reassure investors about possible future revenue declines from Jakafi.

Incyte Corporation (INCY) Q3 2024 Earnings Call Transcript
seekingalpha.com29 October 2024 Sentiment: POSITIVE

Incyte Corporation will hold a conference call on October 29, 2024, at 8:00 AM ET to discuss their Q3 2024 financial results. Key company participants include the CEO, CFO, and other executives, along with various analysts from major financial institutions. The call will be recorded for future reference.

INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales
zacks.com29 October 2024 Sentiment: POSITIVE

Incyte has shared mixed results for the third quarter, with earnings falling short of expectations, but revenues exceeding them thanks to higher sales of Jakafi and Opzelura.

Here's What Key Metrics Tell Us About Incyte (INCY) Q3 Earnings
zacks.com29 October 2024 Sentiment: POSITIVE

The main figures for Incyte (INCY) provide an overview of the company's performance for the quarter that ended in September 2024. However, it could be useful to compare these important metrics with Wall Street's predictions and the results from the same period last year.

Incyte raises 2024 sales forecast for top-selling drug Jakafi
reuters.com29 October 2024 Sentiment: POSITIVE

Incyte exceeded Wall Street's expectations for its third-quarter revenue and increased its annual sales prediction for its best-selling drug on Tuesday, thanks to strong patient demand.

Incyte (INCY) Q3 Earnings Miss Estimates
zacks.com29 October 2024 Sentiment: NEUTRAL

Incyte (INCY) reported quarterly earnings of $1.07 per share, which is lower than the Zacks Consensus Estimate of $1.12 per share. This is also a decrease from the earnings of $1.10 per share from the same period last year.

Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura
benzinga.com29 October 2024 Sentiment: POSITIVE

On Tuesday, Incyte Corporation (INCY) announced its revenue for the third quarter, which reached $1.14 billion. This figure represents a 24% increase compared to the same period last year and exceeds the expected amount of $1.08 billion.

Incyte Named One of Top 5 Companies on Science Magazine's 2024 Top Employers List
businesswire.com24 October 2024 Sentiment: POSITIVE

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #SCTopEmployers--Incyte has been recognized as one of the top five companies in Science Magazine's 2024 Top Employers List.

Incyte Gears Up to Report Q3 Earnings: Here's What You Should Know
zacks.com22 October 2024 Sentiment: POSITIVE

INCY's earnings for the third quarter of 2024 are expected to increase due to higher sales of Jakafi and Opzelura.

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com07 October 2024 Sentiment: NEUTRAL

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte has announced inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4).

What type of business is Incyte?

Incyte Corporation is a biopharmaceutical company. The company offers the drug JAKAFI for the treatment of myelofibrosis and polycythemia, as well as Iclusig, a kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Its clinical products include ruxolitinib, a Phase III drug for steroid-refractory chronic graft-versus-host disease (GVHD); and Phase II drug for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company is developing itacitinib, which is in Phase III clinical trials for the treatment of naïve chronic GVHD; and pemigatinib, which is in Phase II clinical trials for the treatment of bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and tumor-agnostic syndrome. The company is also involved in the development of Parsaclisib, which is in Phase II clinical trials for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. The company is developing INCMGA0012, which is in Phase II clinical trials for high-grade endometrial MSI cancer, Merkel

What sector is Incyte in?

Incyte is in the Healthcare sector

What industry is Incyte in?

Incyte is in the Biotechnology industry

What country is Incyte from?

Incyte is headquartered in United States

When did Incyte go public?

Incyte initial public offering (IPO) was on 04 November 1993

What is Incyte website?

https://www.incyte.com

Is Incyte in the S&P 500?

Yes, Incyte is included in the S&P 500 index

Is Incyte in the NASDAQ 100?

No, Incyte is not included in the NASDAQ 100 index

Is Incyte in the Dow Jones?

No, Incyte is not included in the Dow Jones index

When was Incyte the previous earnings report?

No data

When does Incyte earnings report?

The next expected earnings date for Incyte is 13 February 2025